• Novartis' third-quarter 2026 net income fell 70% to USD 1.2 billion due to lower operating income and higher interest expense.
• Net sales rose to USD 14.52 billion, with volume growth partly offset by generic competition.
• A USD 1.9 billion partial impairment affected del-desiran; the drug missed its Phase III primary endpoint in myotonic dystrophy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novartis AG published the original content used to generate this news brief on October 27, 2026, and is solely responsible for the information contained therein.